Express Pharma

Suven Life receives patent for neuro-degenerative drug


The patents are valid until 2032 and 2025

Suven Life Sciences has been granted a patent each by Eurasia and Norway for a drug used in the treatment of neuro-degenerative diseases.

In a BSE filing, Suven Life said it has been granted “one product patent from Eurasia and one product patent from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.”

The patents are valid until 2032 and 2025, respectively, the company added.

Venkat Jasti, CEO, Suven said, “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”

With the new patents, Suven has a total of 20 granted patent from Eurasia and 6 from Norway.

“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.


Comments are closed.